Ozempic received FDA approval in December 2017, making the branded injectable semaglutide pen about eight years old as a prescription product. But the molecule inside it and the science behind it stretch back decades further, rooted in research on a gut hormone first characterized in the 1980s. The path from basic biology to cultural phenomenon involved lizard venom, a long chain of engineered molecules, and a clinical trial program that kept expanding the drug’s reach well beyond its original purpose.
The Gut Hormone That Started It All
The story begins not with Ozempic but with glucagon-like peptide-1, or GLP-1, a hormone your gut releases after you eat. GLP-1 stimulates insulin secretion, slows stomach emptying, and signals the brain that you’ve had enough food. Researchers spent more than 30 years discovering, characterizing, and developing GLP-1 into a usable therapy, work that was eventually recognized by the 2017 Harrington Award Prize for Innovation in Medicine.1PubMed Central. Discovery, characterization, and clinical development of the glucagon-like peptides The problem with natural GLP-1 was always the same: it breaks down in the body within minutes. Injecting it as-is would require constant infusions, which made it impractical as a drug. Solving that problem took two separate lines of research that unfolded in parallel.
One breakthrough came from an unlikely source. In the 1990s, researchers studying the venom of the Gila monster, a venomous lizard native to the American Southwest, isolated a peptide called exendin-4. It shared about 53% of its structure with human GLP-1 but was far more stable in the bloodstream.2PubMed. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent A synthetic version of that lizard peptide, exenatide, reached the market in 2005 under the brand name Byetta, becoming the first GLP-1-based diabetes drug.3PubMed Central. The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill Exenatide proved the concept worked in humans, but it still required twice-daily injections. The pharmaceutical race was on to build a longer-lasting GLP-1 drug.
Engineering the Semaglutide Molecule
Rather than borrowing from reptile biology, Novo Nordisk took the other path: modifying human GLP-1 itself to make it last longer. Their first major success was liraglutide, approved in 2010 as Victoza. Liraglutide lasted long enough for once-daily dosing, a real improvement, but the company kept pushing for a once-weekly version. That effort produced semaglutide.
The molecular engineering was precise. Researchers made a single amino acid swap at one position on the GLP-1 backbone, replacing alanine with a synthetic amino acid resistant to the enzyme that normally chews up GLP-1. They then attached a long fatty acid chain (a C18 di-acid) through a specially designed chemical linker, which caused the molecule to latch onto albumin, a protein abundant in blood. Bound to albumin, semaglutide circulates for roughly a week before clearing, which is what makes once-weekly dosing possible.4Frontiers in Endocrinology. The Discovery and Development of Liraglutide and Semaglutide The result was a molecule that hit the GLP-1 receptor with high potency even while tethered to albumin, and that resisted breakdown far longer than anything that came before.
Clinical Trials and the SUSTAIN Program
With the molecule in hand, Novo Nordisk launched the SUSTAIN clinical trial program, a series of phase 3 trials enrolling more than 8,000 patients with type 2 diabetes. Across SUSTAIN 1 through 7, injectable semaglutide consistently outperformed every comparator tested in lowering both blood sugar and body weight.5PubMed. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials In a head-to-head trial against canagliflozin, a popular SGLT2 inhibitor, semaglutide delivered meaningfully greater reductions in both blood sugar and weight.6The Lancet Diabetes & Endocrinology. Efficacy and safety of once-weekly semaglutide versus canagliflozin in patients with type 2 diabetes (SUSTAIN 8)
Early mechanistic studies helped explain the results. In a randomized, placebo-controlled trial, semaglutide roughly tripled first-phase insulin secretion in response to an intravenous glucose challenge and brought insulin secretion rates in participants with type 2 diabetes up to levels resembling those of healthy individuals.7PubMed Central. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial In other words, the drug wasn’t just forcing insulin out; it was restoring part of the normal insulin response that diabetes erodes.
One SUSTAIN trial stands apart. SUSTAIN 6 was designed as a cardiovascular safety study, the kind regulators require to ensure a diabetes drug isn’t secretly causing heart attacks. Instead of just proving safety, it showed benefit. Major cardiovascular events (heart attacks, strokes, and cardiovascular death combined) occurred in about 6.6% of patients on semaglutide compared with 8.9% on placebo, a relative risk reduction of 26%. Nonfatal stroke dropped by nearly 40%.8PubMed. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes That finding shifted the conversation around semaglutide from “good diabetes drug” to “potentially cardioprotective medication,” and it set the stage for much larger cardiovascular studies later.
FDA Approvals and the Expanding Brand Family
The FDA approved injectable semaglutide for type 2 diabetes in December 2017, and Novo Nordisk launched it as Ozempic. The 0.5 mg and 1 mg once-weekly doses became the standard prescriptions for blood sugar management. But the company was already working on two parallel expansions: an oral version and a higher-dose injection aimed at obesity.
The oral formulation was a technical achievement in itself. Peptide drugs are normally destroyed by stomach acid, so delivering semaglutide as a pill required co-formulating it with an absorption enhancer developed over more than 30 years. The resulting product, Rybelsus, went through the 10-trial PIONEER clinical program and was shown to lower blood sugar and weight comparably to the injection.9PubMed. Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery Rybelsus earned FDA approval in September 2019, becoming the first GLP-1 drug available as a daily tablet. Phase 1 and 2 studies for the oral version had already demonstrated dose-dependent reductions in blood sugar and body weight with an acceptable safety profile, and pharmacological evaluations of interactions with food and other medications helped establish the fussy dosing rules patients now follow: take it on an empty stomach with a small sip of water, then wait at least 30 minutes before eating or drinking anything else.10PubMed Central. Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: focusing on early phase clinical trials
The weight-loss version came next. Wegovy, a 2.4 mg once-weekly semaglutide injection (more than double the highest Ozempic dose), received FDA approval on June 4, 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related condition.11PubMed Central. Semaglutide for the treatment of overweight and obesity: A review So by mid-2021, Novo Nordisk had three semaglutide brands on the market, each filling a different niche: Ozempic for diabetes, Rybelsus for diabetes patients who preferred a pill, and Wegovy for weight loss.
The STEP Trials and the Weight-Loss Conversation
Wegovy’s approval rested on the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program, a series of phase 3 trials that generated results striking enough to reshape public expectations about what a medication could do for weight. The trials were published between 2021 and 2022 and tested the 2.4 mg weekly dose in various populations, including people with and without diabetes, people receiving intensive lifestyle interventions, and adolescents.12The American Journal of Cardiology. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
The adolescent trial deserves special mention. In teenagers aged 12 and older with obesity, semaglutide produced an average BMI reduction of about 16% over 68 weeks, compared with a slight increase in the placebo group. Nearly three-quarters of adolescents on semaglutide lost at least 5% of their body weight, versus fewer than one in five on placebo.13PubMed Central. Once-Weekly Semaglutide in Adolescents with Obesity These results, along with data from liraglutide trials in younger patients, established that GLP-1 drugs were both safe and effective in adolescents with obesity.14Nature Reviews Endocrinology. Current and future pharmacotherapies for obesity in children and adolescents Pediatric obesity has been notoriously difficult to treat with lifestyle changes alone, so these findings opened a new clinical avenue.
SELECT and the Heart Disease Pivot
If SUSTAIN 6 hinted at cardiovascular benefits, the SELECT trial confirmed them on a massive scale. SELECT enrolled more than 17,600 adults who had existing cardiovascular disease and were overweight or obese but did not have diabetes. Over an average follow-up of about 40 months, semaglutide 2.4 mg reduced major adverse cardiovascular events (death from cardiovascular causes, nonfatal heart attack, or nonfatal stroke) by 20% compared with placebo.15PubMed. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes The finding was significant because it demonstrated cardiovascular protection independent of blood-sugar lowering, a result the American College of Cardiology flagged as a meaningful addition to the evidence base.16American College of Cardiology. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity – SELECT
An exploratory analysis of SELECT data went further, showing that semaglutide reduced hospital admissions across the board. Patients on the drug were less likely to be hospitalized for any reason, with total admission rates running roughly 10% lower than in the placebo group.17JAMA Cardiology. Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial Whether this reflects the direct cardiovascular benefit, the weight loss, or some combination remains an open question, but the practical implication for healthcare systems is hard to miss.
Beyond Diabetes and Obesity
Semaglutide’s story has kept expanding into territory its designers probably didn’t anticipate. The FLOW trial, published in 2024, tested semaglutide in patients with type 2 diabetes and chronic kidney disease, a population with limited treatment options. The drug reduced the risk of kidney disease progression or cardiovascular death by about 24%, and the kidney-specific benefit held up on its own.18PubMed. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Regulatory agencies had already approved various semaglutide formulations between 2017 and 2021, and ongoing research is now focused on metabolic liver disease and other conditions where obesity and metabolic dysfunction drive organ damage.19PubMed Central. Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders
Some of the most intriguing signals are coming from addiction research. Preclinical studies show that GLP-1 receptor agonists reduce intake and relapse-like behavior across substances including alcohol, nicotine, and cocaine. Early-phase clinical trials suggest they are safe in this context and may reduce craving.20PubMed Central. Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights The underlying idea is that GLP-1 receptors sit in brain reward circuits, and activating them may dial down the reinforcement signal that drives compulsive behavior, whether the target is food, alcohol, or something else.21Frontiers in Pharmacology. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies This line of research is still young, with most evidence coming from animal models and small human trials, but it has attracted serious attention from addiction researchers.
Shortages, Social Media, and the Counterfeit Problem
Ozempic and Wegovy’s surge in popularity, driven in part by celebrity use and social media promotion, outpaced Novo Nordisk’s manufacturing capacity. Global shortages complicated treatment for the patients who needed semaglutide most: people with type 2 diabetes who had been stable on the drug and suddenly couldn’t fill their prescriptions.22PubMed Central. Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance The shortage also created fertile ground for counterfeit and compounded products. An illicit market emerged online, where buyers could obtain semaglutide without a prescription in formulations that were sometimes counterfeit, low quality, or poorly tolerated.
Compounding pharmacies entered a gray area during the shortage. Under U.S. law, compounders can produce copies of drugs that are in shortage, but the quality and dosing consistency of compounded semaglutide has been questioned by regulators and physicians alike. Reports of adverse events tied to compounded or counterfeit products have prompted safety warnings from the FDA and other agencies. For patients, the practical lesson is straightforward: if you’re getting semaglutide from anywhere other than a licensed pharmacy dispensing the branded product, the risk profile is genuinely unknown.
What Happens When the Patents Expire
Semaglutide’s patent landscape is set to shift in 2026. An analysis of global patent databases found that 12 countries where semaglutide patents expire that year account for nearly half of the world’s obesity and type 2 diabetes burden. Add in 150 additional countries where no semaglutide patents were ever filed, and by the end of 2026, generic injectable semaglutide could theoretically become available in 162 countries representing about 69% of global type 2 diabetes and 84% of clinical obesity.23PubMed Central. How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access
Whether generic production actually materializes at scale is another matter. Peptide drugs are harder to manufacture than small-molecule generics like metformin. They require specialized production facilities and rigorous quality control, which limits how quickly competitors can ramp up. Still, the cost implications are enormous. Branded semaglutide runs well over $1,000 per month in the United States without insurance, and production cost analyses suggest generic versions could be manufactured for a fraction of that. The gap between what the drug costs to make and what patients pay has become one of the most contentious issues in metabolic medicine.
A Quick Timeline at a Glance
For readers who want the milestones in order:
- 1980s–1990s: GLP-1 discovered and characterized as a key insulin-stimulating hormone. Researchers identify its therapeutic potential but face the problem of rapid breakdown in the body.
- 1992: Exendin-4, a GLP-1 mimic, isolated from Gila monster venom. Its natural stability points toward a solution.
- 2005: Exenatide (Byetta), the synthetic version of exendin-4, becomes the first GLP-1 drug on the market.
- 2010: Liraglutide (Victoza), Novo Nordisk’s first human GLP-1 analogue, approved for once-daily injection in type 2 diabetes.
- 2012–2016: Semaglutide enters clinical trials. The SUSTAIN program runs through phases 2 and 3.
- 2016: SUSTAIN 6 results published, showing a 26% reduction in major cardiovascular events.
- 2017: FDA approves injectable semaglutide as Ozempic for type 2 diabetes (December).
- 2019: Rybelsus (oral semaglutide) approved, making it the first GLP-1 drug available as a pill.
- 2021: Wegovy (semaglutide 2.4 mg) approved for chronic weight management (June). STEP trial results published.
- 2022–2023: Adolescent trial results published. SELECT trial results show cardiovascular benefit in people with obesity but without diabetes.
- 2024: FLOW trial shows kidney-protective effects in diabetic kidney disease. Shortages and counterfeit concerns intensify globally.
- 2026: Key patents begin expiring, potentially opening the door to generic semaglutide in much of the world.
How Semaglutide Differs From Other GLP-1 Drugs on the Market
Semaglutide isn’t the only GLP-1 drug available, and patients sometimes wonder why their doctor chooses one over another. Exenatide (still sold as Bydureon in an extended-release form) was the pioneer but produces more modest blood sugar and weight effects. Liraglutide, sold as Victoza for diabetes and Saxenda for weight loss, requires daily injections and generally produces less weight loss than semaglutide at equivalent effort. Dulaglutide (Trulicity) is another weekly injection popular for its ease of use, though head-to-head data in the SUSTAIN trials consistently favored semaglutide on both blood sugar and weight outcomes.
The newest entrant is tirzepatide, which activates both the GLP-1 receptor and a second gut hormone receptor called GIP. Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss, has shown even larger weight reductions in some trials. Whether it will eventually overtake semaglutide in prescribing volume depends partly on long-term cardiovascular data still being gathered. For now, semaglutide has the most extensive safety and outcomes dataset of any drug in its class, which is one reason it remains the default choice for many clinicians.
The broader point is that GLP-1 science is no longer a single-drug story. A field that started with venom from a desert lizard in the early 1990s has produced an entire drug class that is reshaping how medicine approaches diabetes, obesity, heart disease, and possibly conditions no one originally had in mind. Semaglutide’s eight years on the market represent the middle of that story, not the end.